Published Date: 25 Apr 2023
The case study of child abuse and neglect during the Covid-19 pandemic is used in this article to summarize the method for using Google searches to gauge epidemiologic constructs.
Read Full NewsMRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.
Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.
Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.
A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.
1.
Adjuvant ICIs: A Winner and a Loser in Clear Cell Renal Cell Carcinoma?
2.
BlurryScope: A compact, AI-powered microscope for rapid, cost-effective cancer scoring
3.
Telemedicine services linked to reducing excess mortality
4.
It Is Cancer in Kate Middleton.
5.
Oncology Drug Shortages Persist, but Continue to Evolve
1.
How AI is Transforming Diagnostics, Drug Discovery, and Personalized Oncology
2.
Antibody-Drug Conjugates in Oncology: Breakthroughs, Clinical Updates, and Pipeline Innovation
3.
Obesity is a major risk factor for cancer
4.
How Bispecific Antibodies are Redefining Medical Oncology in the US - A 2025 Review
5.
The Statistical Paradigm of Leukemia: From Evolving Epidemiology and Molecular Stratification to Precision Therapies and Future Horizons in Leukemia
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
3.
Efficient Management of First line ALK-rearranged NSCLC - Part V
4.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
5.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation